CIRCA-MED WP1 & WP3 - Circadian Rhythms in ICU Patients
Retrospective Characterization of Circadian Rhythms Using Vital Signs and Other Routine Data From Patients in the Intensive Care Unit
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
-
Berlin, Germania, 10117
- Institute of Medical Informatics, Charite University, Berlin
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
Primary Retrospective Cohort:
- Admitted to and treated in a participating Intensive Care Unit (ICU) between 2017 and 2024
- Minimum ICU length of stay of 3 days (≥ 72 hours)
- Age ≥ 18 years at the time of ICU admission
- All genders (male, female, diverse)
Cohorts from previous studies:
- Prior enrollment in one of the designated parent study protocols
- Availability of supplementary biological or metabolic data (e.g., clock gene expression, melatonin levels) suitable for exploratory association analyses
Exclusion Criteria:
- None
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
All retrospective patients between 2017 and 2024
Relates to retrospective data from all patients who spent at least three days in participating intensive care units at Charite University, Berlin, Germany between 2017 and 2024
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
|
Pa-COVID (DRKS00021688)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
SeptiCLOCK (NCT02044575)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
VITALITY (NCT02143661)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
TRG-N (ISRCTN77569430)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
These exposures represent metabolic consequences of critical illness: insulin sensitivity, muscle atrophy, and critical illness myopathy or ICU-acquired weakness.
|
|
CIPCIM2 (ISRCTN19392591)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
These exposures represent metabolic consequences of critical illness: insulin sensitivity, muscle atrophy, and critical illness myopathy or ICU-acquired weakness.
|
|
CGM (NCT02296372)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
|
HELIA-ICU (NCT05556811)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
These exposures reflect biological clock function: clock gene expression (if available in some cases), and melatonin levels.
|
|
PICS-Analyse (EA1/229/24)
|
These are the primary exposures and are used to detect oscillatory patterns and characterize circadian rhythms.
They include heart rate, body temperature, blood pressure, blood glucose, and insulin.
These are secondary exposures that may influence circadian rhythms: illness severity (e.g., Sequential Organ Failure Assessment (SOFA) score), sedation levels, organ support therapies (e.g., ventilation, dialysis, Extracorporeal Membrane Oxygenation (ECMO)), and medications administered during ICU stay (e.g., sedatives, vasopressors, corticosteroids).
These exposures represent complications that may be associated with circadian disruption: delirium, deep sedation, ICU-acquired muscle weakness, and post-intensive care syndrome.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Characterization of circadian periodicities and classification of time-varying patterns based on routine clinical data
Lasso di tempo: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Assessment of periodicities and time-varying patterns in routine clinical parameters, including heart rate, body temperature, blood pressure, blood glucose, and insulin levels.
Time-series analysis will be conducted to extract continuous metrics (amplitude, period, and phase).
Based on these metrics, patients will be classified into distinct categorical groups according to their periodic oscillation profiles.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Association between circadian rhythm category and clinical severity scores
Lasso di tempo: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Relationship between circadian rhythm classification and illness severity (e.g., SOFA score), sedation level, and use of organ support therapies.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
|
Association between circadian rhythm disruption and critical illness-related conditions
Lasso di tempo: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks), and post-ICU period (up to 3 and 6 months).
|
Presence of delirium, ICU-acquired muscle weakness/critical illness myopathy, and PICS in relation to circadian rhythm category.
Delirium will be measured with the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) binary scale (Positive/Negative).
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks), and post-ICU period (up to 3 and 6 months).
|
|
Association between time-varying clinical patterns and external biological markers (from other studies)
Lasso di tempo: Depending on individual study protocols, from ICU admission through 24 months post-discharge. Sampled daily to weekly during the ICU stay, followed by post-discharge examinations conducted at variable monthly intervals (a maximum of 5 visits).
|
Exploratory associations between oscillatory trends in routine clinical data and biological markers reported in other studies, such as clock gene expression, melatonin levels, insulin sensitivity, muscle atrophy, and critical illness myopathy.
Only associations will be evaluated.
|
Depending on individual study protocols, from ICU admission through 24 months post-discharge. Sampled daily to weekly during the ICU stay, followed by post-discharge examinations conducted at variable monthly intervals (a maximum of 5 visits).
|
|
Feasibility and Data Infrastructure for Real-Time Circadian Visualization (Chrono-Apps)
Lasso di tempo: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Evaluation of the technical feasibility and data integration requirements for generating real-time circadian visualizations within the Patient Data Management System (PDMS).
Feasibility will be assessed based on data completeness, sampling frequency compliance, latency of time-series data streaming from routine ICU monitors, and system stability required to display continuous circadian profiles via Chrono-Apps.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
|
Performance of Algorithm-Based Light Therapy Recommendations
Lasso di tempo: From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Retrospective evaluation of the accuracy and stability of the time-series analysis designed to estimate circadian phase of routine clinical data (vital signs) and generate individualized lighting schedules.
|
From ICU admission to ICU discharge or death, whichever comes first (expected average duration of 4 weeks).
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- EA1/284/22
- 541063275 - TRR 418 (Altro numero di sovvenzione/finanziamento: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .